Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
about
Medical management of brain tumors and the sequelae of treatment.Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients treated with standard chemoradiotherapy.Analysis of the risk factors for myelosuppression after concurrent chemoradiotherapy for patients with advanced non-small cell lung cancer.Can dosimetric parameters predict acute hematologic toxicity in rectal cancer patients treated with intensity-modulated pelvic radiotherapy?Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.MGMT gene variants, temozolomide myelotoxicity and glioma risk. A concise literature survey including an illustrative case.Toxicity after radiochemotherapy for glioblastoma using temozolomide--a retrospective evaluation.Glutathione S-transferase P1 single nucleotide polymorphism predicts permanent ototoxicity in children with medulloblastoma.The role of temozolomide in the management of patients with newly diagnosed anaplastic astrocytoma: a comparison of survival in the era prior to and following the availability of temozolomide.Advances in malignant glioma drug discovery.Hepatotoxicity by combination treatment of temozolomide, artesunate and Chinese herbs in a glioblastoma multiforme patient: case report review of the literature.Toward Personalized Targeted Therapeutics: An Overview.Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts.Hematologic adverse events associated with temozolomide.Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy.The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) Resource in Neuro-Oncology.Persistent bone marrow depression following short-term treatment with temozolomide.A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Suppresses Cell Migration and Invasion in Monomorphic Malignant Human Glioma Cells by Inhibiting FAK/STAT3 Signaling.
P2860
Q26992174-1722ECA7-AA4B-4F8F-B696-BF043572D953Q33400189-DC927F8B-0A1D-4C29-9BD4-73283E1559EFQ33403054-0D0D64E2-6E68-4F99-977C-B40CDCE10CE9Q33424898-2A8A8037-F7E7-4338-943F-DC9D93D5E5C1Q33429506-1DAC6A5C-9C9A-4DA9-BE21-446C353DE0C2Q33441287-D1BD4247-7932-45AC-8A59-B6F3140BB919Q35541071-5E071444-173A-4083-8747-D243AFE6E656Q36546317-8825B1E6-F1AF-48B5-BACF-407E9A422B49Q36676389-3E1AE562-1CA1-42CE-BAD1-EEEEC56B6098Q38014949-24113A8A-2087-4882-A7C6-59CD06085703Q38926305-9918CD4E-4D71-4492-82E9-AD9CD2E8475FQ39044141-F17A9D02-7AF3-4886-AAB2-B88B4D334895Q39417407-1498F340-C84C-4681-B1D1-9D4D45DCA4BAQ43998950-9E905BE4-84A8-42CA-8BCD-09A5CACCBA75Q47577963-E40D829C-4AFF-40DA-B131-59858B5B1539Q47755845-D92EBC77-556F-4030-BDFD-CB1796799799Q48056776-8D4522C0-8652-4943-800E-E455FD828D2CQ48152193-1BA1C25C-4098-4F46-8F5D-298D7F685889
P2860
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Risk analysis of severe myelot ...... clinical and genetic factors.
@ast
Risk analysis of severe myelot ...... clinical and genetic factors.
@en
type
label
Risk analysis of severe myelot ...... clinical and genetic factors.
@ast
Risk analysis of severe myelot ...... clinical and genetic factors.
@en
prefLabel
Risk analysis of severe myelot ...... clinical and genetic factors.
@ast
Risk analysis of severe myelot ...... clinical and genetic factors.
@en
P2093
P2860
P1433
P1476
Risk analysis of severe myelot ...... clinical and genetic factors.
@en
P2093
Elizabeth Vera-Bolaños
Mark R Gilbert
Mehmet F Okcu
Melissa Bondy
Renke Zhou
Rochelle Manning
Terri S Armstrong
P2860
P304
P356
10.1215/15228517-2008-120
P577
2009-12-01T00:00:00Z